Obinutuzumab-induced acute thrombocytopenia: Report of two cases and review of literature - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue British Journal of Haematology Année : 2023

Obinutuzumab-induced acute thrombocytopenia: Report of two cases and review of literature

Résumé

Obinutuzumab (GA101) is a humanized anti-CD20 monoclonal antibody used in the treatment of B-cell malignancies. Under rare occasions, obinutuzumab may induce acute and severe thrombocytopenia. However, little is known about this side effect, referred to as "obinutuzumab-induced acute thrombocytopenia" (OIAT). Here, we report 2 cases of OIAT and review the literature to inform the management and outcome of this rare but life-threatening complication. The first case is a 74 year- old woman who was treated with obinutuzumab-Cyclophosphamide, Vincristine, Prednisone (CVP) for a previously untreated follicular lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 376 G/L to 3 G/L the day after treatment. The second case is a 44 year- old woman who was treated with obinutuzumab as a pre-treatment dose (day-8) before glofitamab infusion as a 4th line therapy for mantle cell lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 76 G/L (due to splenomegaly and bone marrow involvement) to 3 G/L the day after treatment. OIAT is a rare but life-threatening complication. Physicians should be aware of this adverse event to optimally detect and treat this complication.

Domaines

Hématologie

Dates et versions

hal-04122395 , version 1 (08-06-2023)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Yaquine Mechelfekh, Audrey Pontrucher, Jérôme Paillassa, Marie Templé, Roch Houot. Obinutuzumab-induced acute thrombocytopenia: Report of two cases and review of literature. British Journal of Haematology, 2023, 202 (1), pp.168-172. ⟨10.1111/bjh.18826⟩. ⟨hal-04122395⟩
18 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More